Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by GABRIELA RONDON and RIMA M SALIBA.
GABRIELA RONDON
Connection Strength
3.780
RIMA M SALIBA
  1. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant. 2008 Aug; 14(8):859-66.
    View in: PubMed
    Score: 0.323
  2. SIRPa Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies. Front Immunol. 2022; 13:904718.
    View in: PubMed
    Score: 0.212
  3. Mismatch in SIRPa, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. Blood Adv. 2021 09 14; 5(17):3407-3417.
    View in: PubMed
    Score: 0.200
  4. Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. Haematologica. 2021 01 01; 106(1):269-274.
    View in: PubMed
    Score: 0.191
  5. Endothelial Activation and Stress Index (EASIX) at Admission Predicts Fluid Overload in Recipients of Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 05; 26(5):1013-1020.
    View in: PubMed
    Score: 0.179
  6. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood. 2018 03 15; 131(11):1248-1257.
    View in: PubMed
    Score: 0.156
  7. General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1284-90.
    View in: PubMed
    Score: 0.127
  8. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant. 2012 Jan; 47(1):125-31.
    View in: PubMed
    Score: 0.097
  9. Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. Bone Marrow Transplant. 2009 May; 43(9):685-92.
    View in: PubMed
    Score: 0.082
  10. Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. Haematologica. 2005 Dec; 90(12):1725-6.
    View in: PubMed
    Score: 0.067
  11. Corrigendum to 'Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment after Hematopoietic Cell Transplantation' [Transplantation and Cellular Therapy 29/3 (2023) 204-204]. Transplant Cell Ther. 2024 Nov 17.
    View in: PubMed
    Score: 0.062
  12. A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission. Transplant Cell Ther. 2024 Sep 26.
    View in: PubMed
    Score: 0.062
  13. Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation. Blood Adv. 2024 03 12; 8(5):1128-1136.
    View in: PubMed
    Score: 0.060
  14. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2024 May; 24(5):e196-e204.
    View in: PubMed
    Score: 0.059
  15. Hematopoietic cell transplantation can be safely performed after COVID-19. Bone Marrow Transplant. 2023 12; 58(12):1410-1412.
    View in: PubMed
    Score: 0.058
  16. Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment after Hematopoietic Cell Transplantation. Transplant Cell Ther. 2023 03; 29(3):204.e1-204.e7.
    View in: PubMed
    Score: 0.055
  17. HLA Factors versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther. 2023 03; 29(3):189-198.
    View in: PubMed
    Score: 0.054
  18. Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation. Transplant Cell Ther. 2022 10; 28(10):695.e1-695.e10.
    View in: PubMed
    Score: 0.053
  19. Mycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors? Transplant Cell Ther. 2022 08; 28(8):500.e1-500.e10.
    View in: PubMed
    Score: 0.053
  20. Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2022 07; 28(7):395.e1-395.e11.
    View in: PubMed
    Score: 0.052
  21. Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era. Blood Adv. 2021 12 28; 5(24):5599-5607.
    View in: PubMed
    Score: 0.051
  22. Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2021 12; 27(12):1003.e1-1003.e13.
    View in: PubMed
    Score: 0.050
  23. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021 07 27; 5(14):2799-2806.
    View in: PubMed
    Score: 0.050
  24. Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. Transplant Cell Ther. 2021 08; 27(8):689-695.
    View in: PubMed
    Score: 0.049
  25. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 07; 56(7):1746-1749.
    View in: PubMed
    Score: 0.048
  26. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther. 2021 03; 27(3):243.e1-243.e6.
    View in: PubMed
    Score: 0.048
  27. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. Transplant Cell Ther. 2021 03; 27(3):272.e1-272.e5.
    View in: PubMed
    Score: 0.048
  28. Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients. Bone Marrow Transplant. 2021 03; 56(3):745-748.
    View in: PubMed
    Score: 0.047
  29. Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma. Leuk Lymphoma. 2020 12; 61(13):3101-3111.
    View in: PubMed
    Score: 0.046
  30. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant. 2019 07; 25(7):1340-1346.
    View in: PubMed
    Score: 0.042
  31. Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. Front Immunol. 2018; 9:2444.
    View in: PubMed
    Score: 0.041
  32. Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019 04; 54(4):601-606.
    View in: PubMed
    Score: 0.041
  33. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 11; 24(11):2197-2203.
    View in: PubMed
    Score: 0.040
  34. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood. 2018 06 28; 131(26):2989-2992.
    View in: PubMed
    Score: 0.040
  35. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2018 07; 24(7):1514-1520.
    View in: PubMed
    Score: 0.039
  36. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant. 2018 03; 53(3):315-325.
    View in: PubMed
    Score: 0.039
  37. Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease. Am J Surg Pathol. 2017 Nov; 41(11):1483-1490.
    View in: PubMed
    Score: 0.038
  38. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2018 06; 24(6):1232-1236.
    View in: PubMed
    Score: 0.038
  39. Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood. 2017 06 01; 129(22):3031-3033.
    View in: PubMed
    Score: 0.037
  40. Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol. 2017 Apr; 92(4):331-337.
    View in: PubMed
    Score: 0.036
  41. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol. 2016 10; 91(10):E442-7.
    View in: PubMed
    Score: 0.035
  42. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol. 2016 05; 173(3):444-55.
    View in: PubMed
    Score: 0.034
  43. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2016 Jan; 16(1):36-42.
    View in: PubMed
    Score: 0.034
  44. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica. 2015 Oct; 100(10):1361-70.
    View in: PubMed
    Score: 0.033
  45. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of?Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1948-54.
    View in: PubMed
    Score: 0.033
  46. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1413-7.
    View in: PubMed
    Score: 0.032
  47. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant. 2015 May; 21(5):906-12.
    View in: PubMed
    Score: 0.032
  48. Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biol Blood Marrow Transplant. 2015 May; 21(5):855-9.
    View in: PubMed
    Score: 0.032
  49. The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract. 2014 Aug; 20(4):257-62.
    View in: PubMed
    Score: 0.029
  50. Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Jul; 19(7):1059-64.
    View in: PubMed
    Score: 0.028
  51. Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2013 Jun; 19(6):898-903.
    View in: PubMed
    Score: 0.028
  52. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012 Dec 13; 367(24):2305-15.
    View in: PubMed
    Score: 0.027
  53. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1835-44.
    View in: PubMed
    Score: 0.027
  54. Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. Leuk Lymphoma. 2012 Aug; 53(8):1525-9.
    View in: PubMed
    Score: 0.026
  55. Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. Leuk Lymphoma. 2012 May; 53(5):901-6.
    View in: PubMed
    Score: 0.026
  56. Steroid-Refractory Acute GVHD: Predictors and Outcomes. Adv Hematol. 2011; 2011:601953.
    View in: PubMed
    Score: 0.025
  57. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant. 2012 Apr; 18(4):584-92.
    View in: PubMed
    Score: 0.025
  58. Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1841-5.
    View in: PubMed
    Score: 0.025
  59. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant. 2011 Oct; 17(10):1490-6.
    View in: PubMed
    Score: 0.024
  60. Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatched related donors using HLA typing at 10 loci. Biol Blood Marrow Transplant. 2011 Jun; 17(6):923-9.
    View in: PubMed
    Score: 0.024
  61. Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010 May; 16(5):686-94.
    View in: PubMed
    Score: 0.022
  62. Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1094-9.
    View in: PubMed
    Score: 0.022
  63. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant. 2010 Mar; 45(3):429-36.
    View in: PubMed
    Score: 0.022
  64. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica. 2009 Feb; 94(2):249-57.
    View in: PubMed
    Score: 0.021
  65. The Impact of Pre-Stem Cell Transplant Ferritin Level on Late Transplant Complications: An Analysis to Determine the Potential Role of Iron Overload on Late Transplant Outcomes. Internet J Hematol. 2009; 7(1).
    View in: PubMed
    Score: 0.021
  66. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant. 2004 Mar; 10(3):178-85.
    View in: PubMed
    Score: 0.015
  67. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer. Bone Marrow Transplant. 2003 Jun; 31(12):1157-63.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.